Abstract:Dysfunction in either embryonic or postnatal vascular smooth muscle cells (SMCs) significantly contributes to the progression of various cardiovascular diseases. Therefore, elucidating the molecular mechanisms governing VSMC development and homeostasis is crucial. MYH11 is the most reliable lineage gene for SMCs and has been utilized to develop tamoxifen-inducible Cre driver lines for achieving SMC-specific gene manipulation by crossing with mice carrying the loxP-flanked gene, particularly in adult mice. For studies involving SMCs during embryogenesis, the commonly used constitutive Cre driver is controlled by the Tagln (SM22a) promoter. However, this Cre driver exhibits activity in multiple non-SMC populations, including cardiomyocytes and skeletal muscle precursors, introducing confounding effects. Additionally, most existing SMC-specific Cre drivers are generated using a transgenic approach, raising concerns about random site integration and variable gene copy numbers. To address these limitations, we report a novel Cre mouse model generated by knock-in (KI) of a nuclear-localized Cre recombinase into the Myh11 gene locus using homologous recombination. We confirmed that the Cre activity precisely recapitulates endogenous Myh11 expression by crossing with Rosa26 mTmG or tdTomato reporter mice. Moreover, Myh11-driven Cre can efficiently delete the floxed allele of the transcription factor Tead1 specifically in SMCs. The Tead1 SMC-specific knockout mice did not exhibit an overt phenotype, thereby circumventing the embryonic lethal phenotype mediated by Tagln-driven Cre, as we previously reported. These findings establish this novel Cre driver line as a robust tool for tracing the Myh11-positive SMC lineage and manipulating gene function specifically in SMCs during embryonic development in mice.

Generation of a Transgenic Mouse Model with Chondrocyte-Specific and Tamoxifen-Inducible Expression of Cre Recombinase.

Generation and Characterization of Chondrocyte Specific Cre Transgenic Mice

Transgenic Mice That Express Cre Recombinasein Hypertrophic Chondrocytes

The generation and characterization of novel Col1a1FRT-Cre-ER-T2-FRT and Col1a1FRT-STOP-FRT-Cre-ER-T2 mice for sequential mutagenesis

Generation of a tamoxifen inducible Tnnt2MerCreMer knock‐in mouse model for cardiac studies

Generating Endogenous Myh11-driven Cre Mice for Sex-Independent Gene Deletion in Smooth Muscle Cells

Generation and Characterization of Transgenic Mice Expressing Tamoxifen-Inducible Cre-Fusion Protein Specifically in Mouse Liver.

A tamoxifen-inducible Cre knock-in mouse for lens-specific gene manipulation

Generation of chimeras of glucocorticoid receptor conditional gene targeting mice based on Cre/loxP system

Generation of a novel constitutive smooth muscle cell-specific Myh11-driven Cre mouse model

Tamoxifen-inducible cardiac-specific Cre transgenic mouse using VIPR2 intron

Tamoxifen-inducible podocyte-specific iCre recombinase transgenic mouse provides a simple approach for modulation of podocytes in vivo.

Generation of Tamoxifen-Inducible Tfap2b-CreERT2 Mice Using CRISPR-Cas9.

Temporally Regulated and Tissue-Specific Gene Manipulations in the Adult and Embryonic Heart Using a Tamoxifen-Inducible Cre Protein

Mouse Cre Models for the Study of Bone Diseases

A GCaMP reporter mouse with chondrocyte specific expression of a green fluorescent calcium indicator

Generation and characterization of an inducible renal proximal tubule-specific CreERT2 mouse

Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation

Expression of Cre Recombinase in an Enhancer-Cre Transgenic Mouse

Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues

Direct Reprogramming of Mouse Subchondral Bone Osteoblasts into Chondrocyte-like Cells